Volume | 853,714 |
|
|||||
News | - | ||||||
Day High | 80.30 | Low High |
|||||
Day Low | 79.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
80.28 | 79.50 | 80.30 | 79.57 | 80.76 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,167 | 853,714 | $ 79.81 | $ 68,132,766 | - | 69.44 - 88.2312 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 37,744 | $ 79.57 | USD |
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
27.06B | 499.70M | - | 9.46B | 974M | 1.95 | 27.78 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alcon News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 79.93 | 81.43 | 78.28 | 79.60 | 890,109 | -0.36 | -0.45% |
1 Month | 83.39 | 84.96 | 78.28 | 81.82 | 865,392 | -3.82 | -4.58% |
3 Months | 75.52 | 88.2312 | 74.30 | 82.15 | 912,095 | 4.05 | 5.36% |
6 Months | 72.83 | 88.2312 | 69.44 | 78.18 | 877,977 | 6.74 | 9.25% |
1 Year | 73.72 | 88.2312 | 69.44 | 78.71 | 819,273 | 5.85 | 7.94% |
3 Years | 75.98 | 88.78 | 55.21 | 74.24 | 860,107 | 3.59 | 4.72% |
5 Years | 55.74 | 88.78 | 39.37 | 67.32 | 980,034 | 23.83 | 42.75% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |